Committee defers bill seeking insurer coverage for GLP injectable drugs after fiscal concerns

The House Insurance Committee on April 15 voluntarily deferred House Bill 869, which would require health insurers to provide coverage for certain injectable drugs used to improve glucose levels or for weight loss. Sponsor Representative Lyons framed the proposal as preventive medicine that could reduce long-term health costs but acknowledged uncertainty about long-term savings and short-term fiscal impact.

Lawmakers pressed the sponsor on drug prices and fiscal exposure. Representative Bamberg asked about the $250-per-prescription cap recently discussed in HB 1154; Representative Corrioso flagged a fiscal note figure in committee materials (discussed on the record as $315,000,000) and suggested converting the measure into a study to evaluate long-term savings before mandating coverage. Representative Jordan offered a substantive committee-floor amendment to require insurers to cover 25% of drug costs, but the chair declined to consider a substantive amendment without the 24-hour notice required for committee amendments.

Representative Lyons said he was open to negotiated percentages and to returning with amendments; the sponsor agreed to voluntarily defer the bill so the author and interested members could work on an amendment to bring back at the next meeting.

No committee vote on the bill’s merits was taken; the deferral preserves options for an amendment that the author and colleagues may present later.